

Listing of Claims:

Claims 1-17 (Cancelled)

18. (Previously presented) A pharmaceutical formulation comprising olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, produced by homogeneously mixing (a) olanzapine or a pharmaceutically acceptable salt thereof with (b) a monosaccharide and/or oligosaccharide and/or a reduced or oxidised form thereof, (c) a polysaccharide and optionally one or more additional excipients, followed by a direct compression of the mixture into tablets in the absence of any solvent.

19. (Previously presented) The pharmaceutical formulation of claim 18 comprising 40 to 80 weight % of the component (b).

20. (Previously presented) The pharmaceutical formulation of claim 18 comprising 10 to 40 weight % of the polysaccharide.

21. (Previously presented) The pharmaceutical formulation of claim 18 additionally comprising (d) up to 15 weight % of a disintegrant.

22. (Previously presented) The pharmaceutical formulation of claim 18 additionally comprising (e) 5 to 20 weight % of a binder.

23. (Previously presented) The pharmaceutical formulation of claim 18 additionally comprising (f) 0.25 to 5 weight % of a lubricant.

24. (Previously presented) The pharmaceutical formulation of claim 18 additionally comprising (g) 0.1 to 0.5 weight % of a glidant.

25. (Previously presented) The pharmaceutical formulation of claim 18, wherein the component (b) is selected from the group consisting of lactose, sucrose, dextrose, sorbitol, mannitol, lactitol, and mixtures thereof.

26. (Previously presented) The pharmaceutical formulation of claim 25, wherein the component (b) is lactose.

27. (Previously presented) The pharmaceutical formulation of claim 18, wherein the polysaccharide is selected from the group consisting of starch, cellulose, and mixtures thereof.

28. (Previously presented) The pharmaceutical formulation of claim 27, wherein the polysaccharide is cellulose.

29. (Previously presented) The pharmaceutical formulation of claim 28, wherein a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose is used as the components (b) and (c).

30. (Previously presented) The pharmaceutical formulation of claim 29 comprising 70 to 90 weight % of a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose;

8 to 12 weight % of a binder;
3 to 10 weight % of a disintegrant;
0.3 to 2 weight % of a lubricant; and
0.2 to 0.4 weight % of a glidant.

31. (Previously presented) The pharmaceutical formulation of claim 18 comprising olanzapine as the only pharmaceutically active ingredient.

32. (Previously presented) The pharmaceutical formulation of claim 18 having the form of an uncoated tablet.

33. (Cancelled).

34 (New) A pharmaceutical formulation comprising a homogeneous mixture of: (a) uncoated olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient; (b) a monosaccharide and/or oligosaccharide and/or a reduced or oxidized form thereof; (c) a polysaccharide and optionally; d) one or more additional excipients.